Drug Trial Radar · NCT07191353
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
148
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Odense University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bispebjerg Hospital
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 60 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years. The main questions it aims to answer are: Can rapamycin's analog (Everolimus), resistance training, or their combination, enhance bone formation and muscle functions in elderly women compared to non-treatment controls. Participants will be randomized 1:1:1:1 to one of the following treatment regimens: * Oral everolimus 5 mg once a week. * Oral placebo once a week. * Oral everolimus 5 mg once a week plus resistance training RT 1 hour, 3 times weekly. * Oral placebo once a week plus resistance training RT 1 hour, 3 times weekly. During the study there will be a total of 5-7 visits, where the participants will undergo the following: * Blood samles * DXA-, HRpQCT- (only Odense Universitetshospital) and MRI-scans * Muscle- and bone biopsies * Quality of life questionnaires * Testing of muscle funtion * Metabolic studies of muscle and bone protein turnover using labelling with deuturated water
Conditions
- Healthy
- Osteopenia
- Osteoporosis Risk
Interventions
EverolimusDrug
Everolimus 5 mg administered once weekly for 24 weeks
PlaceboDrug
Placebo administered once weekly for 24 weeks
Resistance trainingOther
Resistance training 3 times a week for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- P1NPTime frame: From baseline to end of treatment at 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Institute of Sports Medicine, Bispebjerg Hospital
Bispebjerg, Region Sjælland, Denmark · Recruiting
Department of Endocrinology, Odense University Hospital
Odense, Region Syddanmark, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.